Management of acneiform rashes related to gefitinib therapy.
Purdom
Michelle
M
Department of Cancer Medicine Phase 1 Unit, University of Texas M.D. Anderson Cancer Center, Houston, USA. mpurdom@mdanderson.org
D017322:Clinical Trials, Phase II as Topic; D003131:Combined Modality Therapy; D003879:Dermatologic Agents / Q000008:administration & dosage; D005076:Exanthema / Q000139:chemically induced* / Q000451:nursing / Q000628:therapy*; D005260:Female; D000077156:Gefitinib; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy; D008297:Male; D009062:Mouth Neoplasms / Q000188:drug therapy; D011379:Prognosis; D011799:Quinazolines / Q000009:adverse effects* / Q000627:therapeutic use; D017592:Skin Care / Q000379:methods
D003879:Dermatologic Agents; D011799:Quinazolines; D000077156:Gefitinib